Mirum Pharmaceuticals, Inc.
https://mirumpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirum Pharmaceuticals, Inc.
Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Mirum Targets $500m Sales For Just-Approved Rare Liver Disorder Drug
Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.
Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others
Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals